SCHEMBL692271

SCHEMBL692271

COC(=O)C(C)(C)Oc1ccc(Cl)cc1C=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.51
ERN1 O75460 4/20 0.42
ALDH1A1 P00352 4/20 0.39
HPGD P15428 1/20 0.39
MAPT P10636 5/20 0.39
KMT2A Q03164 7/20 0.39
MEN1 O00255 6/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
PPARA Q07869 2/20 0.38
ABCB11 O95342 1/20 0.38
TSHR P16473 1/20 0.38
HTR2A P28223 1/20 0.38
PMP22 Q01453 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 2/20 0.37
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3038375 0.87 FBP1 (0.50) FBP1ERN1ALDH1A1HPGDMAPT
SCHEMBL1332622 0.85 PPARA (0.53) FBP1ERN1ALDH1A1HPGDMAPT
SCHEMBL1116629 0.85 FBP1 (0.69) FBP1HPGDKMT2AMEN1CYP1A2
SCHEMBL693554 0.82 FBP1 (0.43) FBP1ERN1ALDH1A1HPGDMAPT
SCHEMBL2417929 0.81 MAPT (0.46) ERN1ALDH1A1HPGDMAPTKMT2A
SCHEMBL691591 0.78 ALDH1A1 (0.34) FBP1ERN1ALDH1A1MAPTKMT2A
SCHEMBL2913932 0.78 TSHR (0.44) FBP1ALDH1A1MAPTKMT2AMEN1
SCHEMBL21571752 0.76 FBP1 (0.42) FBP1ERN1ALDH1A1HPGDMAPT
SCHEMBL692884 0.76 MDM2 (0.53) FBP1MAPTKMT2AKDM4ETDP1
SCHEMBL1619277 0.75 SCN9A (0.37) FBP1ERN1HPGDCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421866-A1 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
US-8076482-B2 3,3′-spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2011-12-13 US disclosed
US-8076482-B2 3,3′-spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2011-12-13 US disclosed
US-8076482-B2 3,3′-spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2011-12-13 US disclosed
WO-2010121995-A1 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
WO-2010121995-A1 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100273819-A1 3,3'-Spiroindolinone Derivatives CHEN LI 2010-10-28 US disclosed
US-20100273819-A1 3,3'-Spiroindolinone Derivatives CHEN LI 2010-10-28 US disclosed
US-20100273819-A1 3,3'-Spiroindolinone Derivatives CHEN LI 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273819-A1 3,3'-Spiroindolinone Derivatives SIK3, RB1, CCND3 FBP1 4455/4885ERN1 1293/4885ALDH1A1 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.